Phase 2 Sjogren's Syndrome Trial, Recruiting NCT06991114 Sponsor: Artiva Biotherapeutics, Inc. Condition: Sjogren's Syndrome
Back to Sjogrens Syndrome

Phase 2 Sjogren's Syndrome Trial, Recruiting

NCT06991114
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with Rheumatoid Arthritis (RA):

  • You have a confirmed diagnosis of rheumatoid arthritis based on recognised medical criteria.
  • Your blood tests show a positive result for Rheumatoid Factor (RF) or a related marker called ACPA.
  • Your blood tests show signs of inflammation above a certain level (confirm with trial site).
  • You have already tried a biological treatment for at least 12 weeks, and your doctor has determined it did not work well enough.
  • You currently have at least 6 swollen joints and 6 tender joints.

For people with Sjögren's Disease:

  • You have a confirmed diagnosis of primary Sjögren's Disease based on recognised 2016 criteria, confirmed within the last 24 weeks before joining the trial.
  • Your disease activity score (called clinESSDAI) is above 6, meaning your condition is considered moderately to severely active (confirm with trial site).
  • You still produce a small amount of saliva when tested.

For people with Inflammatory Muscle Disease (IIM):

  • Your blood tests show a positive result for certain immune system markers associated with muscle disease.
  • Your condition has not responded well enough, or you could not tolerate, at least 3 months of steroid treatment and/or at least one other medication that suppresses the immune system.
  • You have had a muscle biopsy or muscle MRI scan confirming your diagnosis within the last 12 months (where applicable).

For people with Systemic Sclerosis (SSc, also known as scleroderma):

  • You have a confirmed diagnosis of systemic sclerosis based on recognised 2013 medical criteria.
  • Your skin thickening score (called mRSS) is greater than 10, indicating significant skin involvement (confirm with trial site).
  • Your diagnosis was first confirmed within the last 8 years.
  • Your condition has not responded well enough, or you could not tolerate, at least 3 months of steroid treatment and/or at least one other immune-suppressing medication.

Who may not be able to join:

  • No specific exclusion criteria were listed in the information provided — please confirm any restrictions directly with the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael Saddekni, M.D., PgDip, BCMAS, Artiva Therapeutics

Phone: 1 858 223 7001

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Artiva Biotherapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
9 July 2025
Est. completion
1 January 2028

Where this trial is recruiting

🇧🇷 Brazil 🇧🇬 Bulgaria 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇵🇱 Poland 🇵🇹 Portugal 🇷🇴 Romania 🇷🇸 Serbia 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov